LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 1235 | 4351 | 4355 | 0.9989 | 0.9988 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 1235 | 4533 | 4277 | 1.0598 | 1.0659 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 1235 | 4567 | 4583 | 0.9964 | 0.9962 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 1235 | 4385 | 4355 | 1.0067 | 1.0073 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 1235 | 4226 | 4277 | 0.9880 | 0.9866 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 1235 | 4185 | 4583 | 0.9131 | 0.9061 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 1235 | 4630 | 4355 | 1.0629 | 1.0683 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 1235 | 4412 | 4277 | 1.0315 | 1.0349 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 1235 | 4289 | 4583 | 0.9358 | 0.9310 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1235 | 4416 | 4355 | 1.0138 | 1.0151 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1235 | 4481 | 4277 | 1.0476 | 1.0526 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1235 | 4190 | 4583 | 0.9142 | 0.9073 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1235 | 4115 | 4355 | 0.9447 | 0.9384 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1235 | 4256 | 4277 | 0.9950 | 0.9944 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1235 | 4119 | 4583 | 0.8987 | 0.8901 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 1235 | 3943 | 4355 | 0.9052 | 0.8933 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 1235 | 3861 | 4277 | 0.9027 | 0.8889 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 1235 | 4041 | 4583 | 0.8817 | 0.8711 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1235 | 4005 | 4474 | 0.8950 | 0.8840 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1235 | 4272 | 4578 | 0.9330 | 0.9280 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1235 | 5057 | 4929 | 1.0259 | 1.0258 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1235 | 3938 | 4474 | 0.8801 | 0.8670 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1235 | 4361 | 4578 | 0.9525 | 0.9491 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 1235 | 4950 | 4929 | 1.0042 | 1.0042 |
MDA-MB-231 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 1235 | 3841 | 4474 | 0.8584 | 0.8420 |